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Introduction
Combined antiretroviral therapy (cART) has dramatically reduced morbidity and mortality 
associated with HIV infection[1–4]. cART restores the immune response against 
opportunistic infections (OIs), but some patients experience an inflammatory reaction within 
weeks or months after cART initiation[5, 6]. This immune reconstitution inflammatory 
syndrome (IRIS), whose pathogenesis is not fully elucidated, can result in clinical worsening 
of existing opportunistic infections after commencing cART (paradoxical IRIS) or in the 
appearance soon after cART initiation of a new and previously unrecognised opportunistic 
infections (unmasking IRIS)[7]. IRIS may be associated with significant morbidity, is a 
diagnostic challenge and complicates clinical management[7].
IRIS has been described in patients with opportunistic infections and AIDS malignancies 
caused by infections [8–17] as well as in patients with non-infectious conditions such as 
rheumatoid arthritis and sarcoidosis, although with a different immunopathogenesis [18, 19]. 
Whereas there is a solid body of literature documenting reactions associated with immune 
restoration for mycobacterial infections both in the HIV-negative[20] and the HIV-positive 
population[21–24], our knowledge of IRIS for other conditions is mainly based upon case 
reports of patients on cART. Most of these describe cases of paradoxical phenomena and 
only few studies have reported on unmasking IRIS. Further, because case definitions have 
not been implemented in large observational databases, it has been problematic to estimate 
its magnitude.
The HIV-CAUSAL Collaboration has recently reported an increase in tuberculosis 
incidence shortly after cART initiation which was particularly marked in patients with CD4 
counts below 50 cells/µL, a pattern strongly suggestive of unmasking IRIS[25]. This pattern 
was not seen for Pneumocystis jirovecii pneumonia. Here we update and extend our study to 
the effect of cART on AIDS-defining events suggested to be associated with IRIS in the 
literature: tuberculosis, mycobacterium avium complex (MAC), cytomegalovirus (CMV) 
retinitis, progressive multifocal leukoencephalopathy (PML), herpes simplex virus, Kaposi 
Sarcoma, Non Hodgkin Lymphoma, cryptococcosis and candidiasis. For each of these 
AIDS-defining events we explore whether changes in incidence after cART initiation are 
compatible with unmasking IRIS.
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We used data from the HIV-CAUSAL collaboration, which includes HIV-positive 
individuals from prospective cohorts in 6 European countries and the United States[25]. All 
cohorts are based on routinely collected data in clinical practice within settings with 
universal access to care. Initiation of cART was defined as the date on which an individual 
initiated treatment with at least two nucleoside reverse transcriptase inhibitors plus either 
one or more protease inhibitors, one nonnucleoside reverse transcriptase inhibitors, one 
entry/fusion inhibitor, or one integrase inhibitor.
Analyses included individuals who were HIV-positive between 1996–2013 aged≥18 years, 
and had a CD4 count and an HIV-RNA measurement within 6 months of each other while 
ART naïve. Individuals’ follow-up started at baseline, defined as the date when all the 
inclusion criteria were met, and ended at outcome diagnosis, death, 12 months after the most 
recent laboratory measurement, or cohort-specific administrative censoring, whichever 
occurred earlier. To prevent the misclassification of undiagnosed prevalent opportunistic 
infections and AIDS malignancies as incident cases and thus minimise the inclusion of cases 
of paradoxical IRIS our analyses excluded HIV-positive individuals who were not AIDS-
free during the baseline month.
Outcomes
We considered as primary outcomes all AIDS-events previously suggested to be associated 
with IRIS. We included tuberculosis, CMV retinitis, cryptococcosis, PML and Kaposi 
Sarcoma because these were the most common AIDS-defining events in a systematic review 
of IRIS in observational studies[11]. We included MAC because its association with IRIS 
was observed soon after antiretroviral therapy was introduced[21]. We included Non-
Hodgkin Lymphoma because rare manifestations of IRIS have been reported[10, 26]. We 
included candidiasis and herpes simplex virus (often not considered in association with 
IRIS) because a large cohort study of cART initiators in the United States[12] reported them 
as the most common IRIS-related events.
The diagnostic criteria for the AIDS-defining events[27] were those routinely used in 
clinical practice in each of the participating countries. Information on use of prophylaxis 
drugs for these conditions is not collected by the HIV-CAUSAL Collaboration because 
prophylaxis for these conditions is not widely implemented in most of the participating 
cohorts.
For each outcome, our working definition for unmasking IRIS was a newly diagnosed and 
non-previously detected AIDS-defining event in the first three months after starting cART.
Statistical methods
All analyses were conducted separately for each outcome. We computed incidence rates as 
number of cases per 1000 person-years and estimated the hazard ratio of each outcome for i) 
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cART versus no cART and ii) no cART versus <3 and ≥3 months since cART initiation. We 
then estimated the cumulative incidence up to 3 months after cART initiation[28].
To estimate the hazard ratios we used a pooled logistic model for risk of the outcome at 
month m+1 that included a time-varying indicator for ever use of cART through month m, 
month of follow-up m (restricted cubic splines with 5 knots) and the following baseline 
covariates: CD4 cell count (<50,50–99,100–199,200–349,350–499, or ≥500 cells/mm3), 
HIV-RNA level (<4,4–5 or >5 log10 copies/mL), sex, transmission group (heterosexual, 
men who have sex with men, injecting drug users, or other/unknown), calendar year (1996–
1998,1999–2000,2001–2003, or 2004–2013), age (<35,35–50, or >50 years), geographical 
origin (Western countries, sub-Saharan Africa, other, or unknown), time since HIV infection 
diagnosis (<3 versus ≥3 months) and cohort.
Because cART is more likely to be initiated in individuals with a low CD4 count and a high 
HIV-RNA level, estimates from the previous models have to be adjusted for these time-
dependent confounders. Because CD4 count and HIV-RNA are affected by prior treatment, 
adding them as time-dependent covariates in the logistic regression model may introduce 
bias[29]. Therefore we used inverse probability weighting to adjust for time-varying CD4 
count and HIV-RNA. Formally, under the assumption that all time-varying predictors of 
both cART and AIDS were included in the analyses, the weighted model estimates the 
parameters of a marginal structural Cox model[30].
Each patient in the analysis received a time-dependent weight inversely proportional to the 
probability of having its own observed history of cART initiation, as described 
elsewhere[30]. To estimate each patient’s probability of cART initiation in each month, we 
fit a pooled logistic model that included the covariates listed above for the outcome model 
plus the most recent measurement of the following time-dependent covariates: CD4 cell 
count (restricted cubic splines with 5 knot), HIV-RNA level (<4, 4–5 or >5 log10 copies/
mL), AIDS (yes or no) and time since last laboratory measurement. Inverse probability 
weights were also estimated to adjust for potential selection bias due to censoring by 
infrequent measurement. Both the cART initiation and censoring weights were stabilized 
and their product used to fit the weighted pooled logistic model. To avoid the influence of 
outliers on the variance of the estimates, we truncated the weights at a maximum of 10 
which affected <1% of the individuals. The estimated weights used in the analyses had a 
mean of 1.01. Truncation did not materially change the hazard ratio estimates. We computed 
conservative 95% confidence intervals for the log hazard ratio by using a variance estimator 
that accounts for the estimation of the weights.
We performed several sensitivity analyses: i) we estimated the hazard ratio of no cART 
versus time since cART initiation categories <4 and ≥4 months, ii) in addition to censoring 
follow-up at 12 months without a laboratory measurement, we censored at 18 and 24 months 
after the last measurement, iii) the start of follow-up was delayed by 3 months to exclude 
prevalent cases, iv) we lagged CD4 count and HIV-RNA level 14 days or 21 days to ensure 
that cART initiation was predicted using prior measurements, v) we estimated inverse 
probability weights for censoring by death (so that estimates can be interpreted as if all 
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deaths could be prevented), and vi) we included patients who started cART during the first 
month after baseline.
All analyses were conducted with SAS, version 9.3.
Results
Our analysis included 96,562 eligible individuals who contributed 377,324 person-years 
during a median [interquantile range (IQR)] follow-up of 31 [13, 65] months. Table 1 shows 
their baseline characteristics: 78% were men and 70% started follow-up after 2000. The 
median [IQR] CD4 cell count, HIV-RNA and age at baseline were 405 [263,570] cells/mm3, 
4.4 [3.8,5.0] log10 copies/mL and 36 [30,43] years, respectively. Fifty-seven % of the 
included patients initiated cART during follow-up; the median [IQR] CD4 cell count, HIV-
RNA and age at cART initiation were 279 [187,380] cells/mm3, 4.7 [4.0,5.2] log10 
copies/mL and 38 (32,46) years, respectively.
The incidence rate (per 1000 person-years) ranged between 2.3 for tuberculosis and 0.3 for 
CMV retinitis and PML. For all outcomes, incidence rates were lower for higher CD4 cell 
count, younger age and lower HIV-RNA level at baseline (Figure 1). Appendix 1 shows the 
number of cases and incidence rates for each outcome by baseline characteristics. The 
hazard ratios (95% confidence intervals) for cART versus no cART were less than 1 for all 
outcomes, and ranged between 0.13 (0.05–0.38) for cryptococcosis and 0.76 (0.58–1.00) for 
herpes simplex infection. Appendix 2 shows the weighted and unweighted hazard ratio 
estimates.
The median [IQR] CD4 cell count at event diagnosis was 291 [161,440] cells/mm3 for 
tuberculosis, 34 [10,189] cells/mm3 for MAC, 38 [10,189] cells/mm3 for CMV retinitis, 185 
[72,310] cells/mm3 for PML, 360 [199,535] cells/mm3 for herpes simplex virus, 322 
[186,457] cells/mm3 for Kaposi Sarcoma, 318 [192,466] cells/mm3 for Non Hodgkin 
Lymphoma, 55 [19,149] cells/mm3 for cryptococcosis and 241 [100,399] cells/mm3 for 
candidiasis.
Table 2 presents the hazard ratios of each outcome by time since initiation of cART. 
Compared with non-cART initiation, the hazard ratios up to 3 months after cART initiation 
were 1.21 (0.90–1.63) for tuberculosis, 2.61 (1.05–6.49) for MAC, 1.17 (0.34–4.08) for 
CMV retinitis, 1.18 (0.62–2.26) for PML, 1.21 (0.83–1.75) for herpes simplex virus, 1.18 
(0.87–1.58) for Kaposi Sarcoma, 1.56 (0.82–2.95) for Non Hodgkin Lymphoma, 1.11 (0.56–
2.18) for cryptococcosis and 0.77 (0.40–1.49) for candidiasis. The hazard ratios ≥3 months 
since cART initiation compared to non-cART initiation ranged between 0.06 (0.02–0.19) for 
cryptococcosis and 0.69 (0.51–0.92) for herpes simplex virus. The hazard ratio up to 3 
months after cART initiation for any of the explored AIDS event compared to non-cART 
initiation was 1.25 (1.05,1.48).
The hazard ratio estimates by time since cART initiation stratified by CD4 cell count, HIV-
RNA level, age and sex for events with more than 500 cases (tuberculosis, Kaposi Sarcoma, 
Non Hodgkin Lymphoma, candidiasis and herpes simplex virus) are presented in 
Appendices 3–7. The risk of tuberculosis up to 3 months after cART initiation was 1.77 
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(0.78,4.00) in patients with baseline CD4 count <50 cells/mm3, 2.10 (1.07,4.11) in patients 
with age>50 years and 1.21 (0.84,1.74) in males.
The hazard ratio estimates did not materially change in sensitivity analyses (Appendix 7). 
The cumulative incidence (95% confidence intervals) at 3 months following cART initiation 
ranged between 0.17% (0.14%- 0.20%) for tuberculosis and 0.02% (0.01%- 0.04%) for 
CMV retinitis. The cumulative incidence for any of the outcomes at 2 months following 
cART initiation was 0.67% (0.60–0.74%).
Discussion
Our study suggests that cART initiation reduces the overall incidence of tuberculosis, MAC, 
CMV retinitis, PML, Herpes Simplex virus, Kaposi Sarcoma, Non Hodgkin Lymphoma, 
cryptococcosis and candidiasis. In spite of this net overall reduction, there was evidence of 
an increased risk of MAC up to 3 months after cART initiation. The 3-month risk was also 
slightly elevated for tuberculosis, CMV retinitis, Herpes Simplex virus, Kaposi Sarcoma and 
Non Hodgkin Lymphoma, but the 95% confidence intervals were wide. The epidemiological 
patterns observed for MAC and TB are consistent with a relevant proportion of unmasking 
IRIS among the diagnosis; for the other conditions the evidence is less compelling. For 
candidiasis the evidence did not support unmasking IRIS.
Our results build on previous findings reported by the HIV-CAUSAL Collaboration with 
follow-up through 2007. We now report a lower incidence of TB (2.3 versus 3.2 cases per 
1000 person-years) and a lower increase in TB incidence soon after cART initiation (21% 
versus 36%). Since median CD4 cell count at TB diagnosis has not increased over time 
(results not shown), these changes might be explained by a combination of random 
variability, temporal trends in TB incidence, and with enhanced pre-cART screening due to 
increased awareness of TB-related IRIS.
Although IRIS has been most often reported for opportunistic infections, IRIS associated 
with malignancies has also been described[9, 10]. Like previous studies[31, 32], we found 
small increases in risk of Non Hodgkin Lymphoma and Kaposi Sarcoma up to 3 months of 
cART initiation, but the 95% confidence intervals were wide. Given that the development of 
these cancers should be preceded by exposure to causative agents, the increased incidence 
for malignancies up to 3 months after cART initiation is consistent with unmasking IRIS 
leading to increased clinical symptoms and thus diagnostic steps in the case of prevalent 
subclinical cancers.
We also found that the risk at 3 months of cART initiation for any of the events was <0.7%. 
This risk is much lower than that reported in a meta-analysis (between 38% for CMV 
retinitis and 6% for Kaposi Sarcoma)[11] and in the HOPS cohort (between 23% for 
candidiasis and 0.5% for PML)[12]. Because these previous studies were not restricted to 
AIDS-free patients, their risk estimates encompass both paradoxical IRIS and unmasking 
IRIS. In fact, the risk of unmasking IRIS may be even lower because our study cannot 
distinguish cases of unmasking IRIS from new cases unrelated to IRIS. Further 
ascertainment bias may account for some of the cases recorded early after cART initiation, 
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as these might have been previously undiagnosed cases due to more intensive clinical 
screening in newly treated patients. However, the fact that we found no significant initial 
increase in risk despite this potential bias strengthens our conclusions that unmasking IRIS 
for the explored events is not common after cART initiation in patients starting cART in 
recent times in the European and North American setting.
Our study had several limitations. First, like all observational studies the validity of our 
estimates relies on the assumption of no unmeasured confounding. Although we adjusted 
our models for CD4 count and HIV-RNA levels, the most important factors used by 
clinicians to decide whether to start cART, we cannot exclude the possibility that other 
unmeasured variables related to cART initiation could have also played a role. Second, we 
assumed that patients remained on therapy once it was initiated. If the diagnoses of the 
examined AIDS-defining events were largely occurring in individuals who had stopped 
cART or had poor adherence, then we might have underestimated the effect of cART 
initiation on the risk of the explored events. On the other hand, this bias is unlikely to have 
affected our conclusions on the trends in incidence up to 3 months after cART initiation. 
Finally, given the small number of events occurring during the first months of cART for 
some of the outcome events, we could not yet explore whether the effect of cART differed 
by patients characteristics that may be associated with development of IRIS. This is 
particularly important for baseline CD4 count[11, 25] because unmasking IRIS is mainly 
observed in patients with very low CD4 counts, who were a minority in our study 
population.
In summary, this study suggests that, with the exception of mycobacterial infections, 
unmasking IRIS is not common after cART initiation in AIDS-free patients in Europe and 
the United States. In order to make an early diagnosis and provide adequate treatment, 
clinicians should rule out MAC and TB meticulously in patients at risk before starting cART 
and monitor closely for these OIs during the early phases of treatment.
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Appendix 1. Incidence rates (per 1000 person-years) of AIDS-defining 
events overall and by baseline characteristics, HIV-CAUSAL Collaboration 
1996–2013
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Appendix 2. Hazard ratios of AIDS-defining events for cART initiation 









Tuberculosis 0.77 (0.65,0.91) 0.95 (0.80,1.12) 0.48 (0.36,0.64)
MAC 1.12 (0.75,1.69) 1.25 (0.84,1.86) 0.51 (0.27,0.95)
CMV Retinitis 0.86 (0.52,1.42) 0.95 (0.58,1.54) 0.24 (0.09,0.66)
PML 1.04 (0.63,1.72) 1.03 (0.63,1.67) 0.41 (0.15,1.09)
Herpes Simplex Infection 0.97 (0.78,1.19) 1.09 (0.88,1.34) 0.76 (0.58,1.00)
Kaposi Sarcoma 0.53 (0.44,0.64) 0.84 (0.70,1.02) 0.22 (0.15,0.32)
Non Hodgkin Lymphoma 0.88 (0.69,1.11) 0.94 (0.74,1.20) 0.51 (0.36,0.73)
Cryptococcosis 0.46 (0.30,0.70) 0.57 (0.38,0.87) 0.15 (0.05,0.42)
Candidiasis 0.43 (0.34,0.54) 0.73 (0.58,0.90) 0.18 (0.12,0.26)
cART Combined antiretroviral therapy; CMV cytomegalovirus; MAC Mycobacterium avium complex; PML Progressive 
multifocal leukoencephalopathy.
Appendix 3. Hazard ratios of tuberculosis by time since initiation of 




Time since cART initiation, <3
months
Time since cART initiation, ≥3 
months
Baseline characteristics Cases,N HR Cases, N HR Cases, N HR
CD4 count, cells/mm3
<50 16 1 24 1.77 (0.78–4.00) 47 0.61 (0.24–1.56)
50 – 100 21 1 14 0.94 (0.42–2.12) 29 0.38 (0.21–0.63)
100 – 200 44 1 17 0.77 (0.41–1.43) 77 0.37 (0.21–0.63)
200 – 350 107 1 26 0.92 (0.51–1.67) 106 0.28 (0.15–0.53)
≥350 234 1 16 1.06 (0.49–2.28) 120 0.43 (0.29–0.63)
HIV-RNA, log10 copies/mL
<4 113 1 14 1.56 (0.73–3.33) 58 0.45 (0.25–0.81)
4–5 203 1 34 1.25 (0.78–2.01) 177 0.40 (0.27–0.58)
>5 106 1 49 0.96 (0.63–1.47) 144 0.29 (0.16–0.55)
Age, years
< 35 188 1 38 1.2 (0.73–1.98) 157 0.36 (0.24–0.55)
35 – 50 180 1 37 0.9 (0.58–1.40) 172 0.35 (0.21–0.57)
≥50 54 1 22 2.1 (1.07–4.11) 50 0.38 (0.16–0.90)
Sex
Male 288 1 70 1.21 (0.84–1.74) 259 0.31 (0.21–0.47)
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Time since cART initiation, <3
months
Time since cART initiation, ≥3 
months
Baseline characteristics Cases,N HR Cases, N HR Cases, N HR
Female 133 1 27 1.12 (0.67–1.88) 120 0.44 (0.29–0.67)
Appendix 4. Hazard ratios of Kaposi Sarcoma by time since initiation of 




Time since cART initiation, <3
months
Time since cART initiation, ≥3 
months
Baseline characteristics Cases,N HR Cases, N HR Cases, N HR
CD4 count, cells/mm3
<50 21 1 15 0.92 (0.46–1.82) 28 0.24 (0.09–0.65)
50 – 100 13 1 8 0.67 (0.24–1.87) 17 0.12 (0.04–0.39)
100 – 200 30 1 12 0.62 (0.31–1.22) 23 0.05 (0.01–0.19)
200 – 350 81 1 16 0.73 (0.41–1.32) 73 0.16 (0.09–0.29)
≥350 259 1 44 1.76 (1.13–2.74) 108 0.19 (0.12–0.29)
HIV-RNA, log10 copies/mL
<4 59 1 13 1.56 (0.73–3.33) 39 0.31 (0.15–0.64)
4–5 192 1 43 1.25 (0.78–2.01) 115 0.13 (0.07–0.24)
>5 153 1 39 0.96 (0.63–1.47) 95 0.15 (0.09–0.24)
Age, years
< 35 151 1 34 1.2 (0.73–1.98) 77 0.06 (0.03–0.1.2)
35 – 50 198 1 49 0.9 (0.58–1.40) 117 0.19 (0.11–0.33)
≥50 55 1 12 2.1 (1.07–4.11) 55 0.32 (0.15–0.69)
Sex
Male 392 1 89 1.21 (0.84–1.74) 226 0.14 (0.10–0.21)
Female 12 1 6 1.12 (0.67–1.88) 23 0.12 (0.02–0.71)
Appendix 5. Hazard ratios of Non Hodgkin Lymphoma by time since 
initiation of combined antiretroviral therapy and baseline characteristics, 
HIV-CAUSAL Collaboration 1996–2013
No cART initiation
Time since cART initiation, 
<3
months
Time since cART initiation, 
≥3 months
Baseline characteristics Cases, N HR Cases, N HR Cases, N HR
CD4 count, cells/mm3
<50 9 1 3 0.59 (0.25–1.40) 16 0.18 (0.09–0.35)
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Time since cART initiation, 
<3
months
Time since cART initiation, 
≥3 months
Baseline characteristics Cases, N HR Cases, N HR Cases, N HR
50 – 100 9 1 2 0.33 (0.06–1.71) 20 0.08 (0.02–0.29)
100 – 200 15 1 6 0.16 (0.05–0.55) 48 0.15 (0.05–0.44)
200 – 350 40 1 12 1.33 (0.34–5.13) 65 0.11 (0.05–0.25)
≥350 125 1 15 1.52 (0.79–2.93) 103 0.37 (0.23–0.59)
HIV-RNA, log10 copies/mL
<4 54 1 4 0.63 (0.16–22.43) 35 0.49 (0.24–0.99)
4–5 98 1 18 1.20 (0.4–3.52) 108 0.11 (0.06–0.19)
>5 46 1 16 0.44 (0.26–0.74) 109 0.14 (0.09–0.22)
Age, years
< 35 68 1 9 0.26 (0.12–0.58) 63 0.12 (0.06–0.23)
35 – 50 100 1 26 1.24 (0.52–2.95) 116 0.12 (0.07–0.20)
≥50 30 1 3 0.44 (0.15–1.32) 73 0.22 (0.09–0.56)
Sex
Male 163 1 35 0.89 (0.40–1.98) 229 0.13 (0.08–0.21)
Female 35 1 2 0.46 (0.18–1.17) 3 0.13 (0.06–0.26)
Appendix 6. Hazard ratios of Candidiasis by time since initiation of 
combined antiretroviral therapy and baseline characteristics, HIV-CAUSAL 
Collaboration 1996–2013
No cART initiation
Time since cART initiation, 
<3
months
Time since cART initiation, 
≥3 months
Baseline characteristics Cases,N HR Cases, N HR Cases, N HR
CD4 count, cells/mm3
<50 20 1 11 0.59 (0.25–1.40) 29 0.18 (0.09–0.35)
50 – 100 20 1 3 0.33 (0.06–1.71) 20 0.08 (0.02–0.29)
100 – 200 26 1 3 0.16 (0.05–0.55) 41 0.15 (0.05–0.04)
200 – 350 53 1 9 1.33 (0.34–5.13) 47 0.11 (0.05–0.25)
≥350 156 1 10 0.62 (0.22–1.73) 87 0.17 (0.11–0.29)
HIV-RNA, log10 copies/mL
<4 47 1 3 0.63 (0.16–2.43) 32 0.49 (0.24–0.99)
4–5 129 1 12 1.20 (0.41–3.52) 93 0.11 (0.06–0.19)
>5 99 1 21 0.44 (0.26–0.74) 99 0.14 (0.09–0.22)
Age, years
< 35 111 1 8 0.26 (0.12–0.58) 101 0.12 (0.06–0.23)
35 – 50 137 1 24 1.24 (0.52–2.95) 80 0.12 (0.07–0.20)
≥50 27 1 4 0.44 (0.15–1.32) 43 0.22 (0.09–0.56)
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Time since cART initiation, 
<3
months
Time since cART initiation, 
≥3 months
Baseline characteristics Cases,N HR Cases, N HR Cases, N HR
Sex
Male 205 1 27 0.89 (0.40–1.98) 162 0.13 (0.08–0.21)
Female 70 1 9 0.46 (0.18–1.17) 62 0.13 (0.06–0.26)
Appendix 7. Hazard ratios of Herpes Simplex Virus by time since initiation 
of combined antiretroviral therapy and baseline characteristics, HIV-
CAUSAL Collaboration 1996–2013
No cART initiation Time since cART initiation, 
<3
months
Time since cART initiation, 
≥3 months
Baseline characteristics Cases,N HR Cases, N HR Cases, N HR
CD4 count, cells/mm3
<100 23 1 13 1.02 (0.49–2.13) 71 0.38 (0.19–0.78)
100 – 200 15 1 4 0.58 (0.19–1.77) 48 1.02 (0.39–2.64)
200 – 350 41 1 6 0.90 (0.35–2.31) 77 0.98 (0.56–1.71)
≥350 175 1 19 1.43 (0.84–2.43) 128 0.67 (0.46–0.98)
HIV-RNA, log10 copies/mL
<4 92 1 10 1.60 (0.75–3.40) 69 0.74 (0.44–1.24)
4–5 109 1 15 1.11 (0.60–2.04) 142 0.74 (0.49–1.11)
>5 53 1 17 0.97 (0.55–1.73) 113 0.59 (0.29–1.18)
Age, years
< 35 91 1 13 1.04 (0.53–2.01) 87 0.56 (0.33–0.95)
35 – 50 119 1 22 1.58 (0.96–2.59) 181 0.82 (0.55–1.23)
≥50 44 1 7 0.65 (0.26–1.66) 56 0.56 (0.27–1.16)
Sex
Male 216 1 36 1.28 (0.85–1.92) 276 0.68 (0.49–0.93)
Female 38 1 6 0.79 (0.31–2.00) 45 0.70 (0.32–1.57)
Appendix 8. Sensitivity analyses. Hazard ratios (95% confidence intervals) 
for combined antiretroviral therapy initiation versus time since cART 
initiation <3 months, HIV-CAUSAL Collaboration 1996–2013
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Incidence rates of AIDS-defining events per 1000 person-year of follow-up, HIV-CAUSAL 
Collaboration 1996–2013
cART Combined antiretroviral therapy; CMV cytomegalovirus; MAC Mycobacterium 
avium complex; PML Progressive multifocal leukoencephalopathy.
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Table 1









  CD4 count, cells/mm3
<50 3522 27 [11, 64] 13088.33 2784 (79%)
50 – 100 3061 33[12, 71] 12360.83 2468 (81%)
100 – 200 8641 34[14, 73] 35951.17 7018 (81%)
200 – 350 21807 33[14, 70] 88392.08 15648 (72%)
350 – 500 24553 31[14, 67] 96822 13854 (56%)
>500 34978 30[13, 62] 130709.67 13372 (38%)
  HIV-RNA, log10 copies/mL
<4 30596 29[13, 61] 114836.42 12650 (41%)
4–5 43419 32[14, 67] 171358 25928 (60%)
>5 22547 34[14, 71] 91129.67 16566 (73%)
  Sex
Male 75049 32[14, 67] 295646.25 43038 (57%)
Female 21513 29[13, 65] 81677.83 12106 (56%)
  Age, years
< 35 44698 30[13, 63] 169760.17 23362 (52%)
35 – 50 40154 33[14, 70] 162430.83 23980 (60%)
≥50 11710 32[12, 67] 45133.08 7802 (67%)
  Transmission group
Heterosexual 30060 31[14, 67] 117387.58 17814 (59%)
Homo/bi-sexual 39971 35[16, 71] 166591.83 23014 (58%)
Injection drug-use 8201 24[11, 56] 29432.17 3817 (47%)
Other/unknown 18330 26[11, 58] 63912.5 10499 (57%)
  Geographical origin
Western Countries 57041 31[13, 67] 224174.75 32765 (57%)
Sub-Saharan Africa 12497 29[13, 62] 44686.75 7453 (60%)
Rest of World 7577 27[13, 55] 25211.42 4054 (54%)
Unknown country 19447 34[15,74] 83251.17 10872 (56%)
  Calendar period
1996 – 1998 20317 38 [14, 118] 112796.42 11251 (55%)
1999 – 2000 8940 40[14, 110] 44845.33 5276 (59%)
2001 – 2003 16639 43[16, 98] 77702 9742 (59%)
2004–2013 50666 27 [12,50] 141980.33 28875 (57%)
Overall 96562 31 [13,65] 377324.08 55144 (57%)
cART. Combined antiretroviral therapy; IQR. Interquantile range.
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Table 2














Tuberculosis No cART 422 143523.33 2.9 1
<3 months 97 9259.00 10.5 1.21 (0.90–1.63)
≥3 months 379 236095.92 1.6 0.36 (0.26–0.49)
Mycobacterium Avium Complex No cART 46 143936.50 0.3 1
<3 months 37 9306.83 4.0 2.61 (1.05–6.49)
≥3 months 80 238799.67 0.3 0.31 (0.16–0.59)
CMV Retinitis No cART 35 143938.83 0.2 1
<3 months 12 9308.42 1.3 1.17 (0.34,4.08)
≥3 months 58 238917.67 0.2 0.13 (0.04–0.39)
PML No cART 38 143944.00 0.3 1
<3 months 19 9307.42 2.0 1.18 (0.62–2.26)
≥3 months 56 238960.75 0.2 0.21 (0.06–0.71)
Herpes Simplex Virus No cART 254 143476.42 1.8 1
<3 months 42 9282.00 4.5 1.21 (0.83–1.75)
≥3 months 324 236713.50 1.4 0.69 (0.51–0.92)
Kaposi Sarcoma No cART 404 143755.17 2.8 1
<3 months 95 9250.67 10.3 1.18 (0.87–1.58)
≥3 months 249 236065.50 1.1 0.14 (0.10–0.21)
Non Hodgkin Lymphoma No cART 198 143875.92 1.4 1
<3 months 38 9288.17 4.1 1.56 (0.82–2.95)
≥3 months 252 237871.50 1.1 0.40 (0.27–0.58)
Cryptococcosis No cART 60 143924.67 0.4 1
<3 months 21 9305.67 2.3 1.11 (0.56,2.18)
≥3 months 58 238860.92 0.2 0.06 (0.02–0.19)
Candidiasis No cART 275 143745.33 1.9 1
<3 months 36 9275.67 3.9 0.77 (0.40–1.49)
≥3 months 224 237213.75 0.9 0.13 (0.09–0.20)
cART Combined antiretroviral therapy; CMV cytomegalovirus; MAC Mycobacterium avium complex; PML Progressive multifocal 
leukoencephalopathy.
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